This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabbatini, P. Search for Related Content PubMed PubMed Citation Articles by Sabbatini, P.

The Relationship between Anemia and Quality of Life in Cancer Patients

Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Paul Sabbatini, M.D., Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-6423; Fax: 212-639-8865; e-mail: sabbatip{at}mskcc.org

Anemia is a common occurrence in patients with cancer, and especially in those who undergo chemotherapy. Traditionally, significantly decreased hemoglobin levels have been considered to be 8 g/dl and have been associated with physiologic manifestations. More recent data have shown that milder anemia (hemoglobin levels 10-12 g/dl) has functional consequences as well. This article reviews several communitybased studies that have analyzed changes in hemoglobin concentrations, transfusion requirements, and QOL parameters in anemic patients with cancer before and after treatment with epoetin alfa. The results of these studies have been consistent and show an increase in hemoglobin and a reduction in transfusion requirements when compared with baseline. Furthermore, a relationship between increasing hemoglobin levels and an improvement in QOL is suggested that is independent of tumor response. Additional studies are evaluating the optimal hemoglobin levels for the greatest incremental improvement in QOL.

Key Words. Functional anemia • Epidemiology • Epoetin alfa • Quality of life • FACT-An

This article has been cited by other articles:

				K. Tolentino and J. F. Friedman An Update on Anemia in Less Developed Countries Am J Trop Med Hyg, July 1, 2007; 77(1): 44 - 51. [Abstract] [Full Text] [PDF]

				M. S. Duh, P. Lefebvre, J. Fastenau, C. T. Piech, and R. J. Waltzman Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve Oncologist, June 1, 2005; 10(6): 438 - 448. [Abstract] [Full Text] [PDF]